4 results
The primary objective is to determine the effect of intravenously administered rhAPC on HDM-LPS induced allergic lung inflammation.
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock compared with placebo.
1. To assess the long-term safety and tolerability of ABBV-8E12 in subjects with early Alzheimer's disease (AD).2. To assess the pharmacokinetics (PK) of ABBV-8E12 in subjects with early AD.The exploratory objectives of this study are:• To…
1. To assess the efficacy of ABBV-8E12 in slowing disease progression (cognitive and functional impairment) in subjects with Early Alzheimer's Disease (AD) as measured by the Clinical Dementia Rating - Sum of Boxes (CDR-SB).2. To assess the…